ClinicalTrials.gg
CompletedNCT04633122Updated Apr 3, 2026Results posted

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

A Phase 2 interventional study of Ripretinib and Sunitinib in Gastrointestinal Stromal Tumor(GIST), sponsored by Zai Lab (Shanghai) Co., Ltd.. Completed at 18 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.

Enrollment
20th of 46
108 · median 100
Started
2020
with 6 others
Phase 2
11 of 69
5 open now
Registered
29th of 69
by date

Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 20th largest by enrollment of the 46 interventional ones that give a count, is one of 7 that started in 2020, is one of 11 in phase 2, and was the 29th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Gastrointestinal Stromal Tumors with a site in China, or all of them as a file.
02

Study summary

the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.

03

Conditions studied

  • Gastrointestinal Stromal Tumor(GIST)

Keywords

  • Gastrointestinal Stromal Tumors,GIST,DCC-2618,Ripretinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥18 years of age.
  • Histological diagnosis of advanced GIST and capability of providing tumor tissue sample (the interval between tumor tissue collection and signing of form should be less than 3 years). Otherwise, is required.
  • Provide molecular test report with KIT/PDGFRA mutation status prior to randomization.
  • Patients must have progressed on imatinib or have documented intolerance to imatinib. Subjects must have discontinued imatinib treatment 10 days prior to the first dose of the study drug. All prior imatinib treatments will be considered as (such as imatinib therapy and imatinib dose increase).
  • PS of 0-2.
  • Female patients of must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening.
  • Patients of must agree to follow the requirements.
  • At least 1 according to the " v1.1-GIST-specific Criteria" (non-nodal lesions must be ≥1.0 cm in the long axis or ≥ double the slide thickness in the long axis) ; obtaining radiographic image results within 28 days prior to the first dose of study drug.
  • Good organ function and bone marrow reserve function, including:

    • ≥ 1,000/µL
    • ≥ 8 g/dL
    • count ≥ 75,000/µL
    • Total ≤ 1.5 × the (ULN)
    • and ALT ≤ 3×ULN, and AST and ALT≤ 5×ULN in the presence of hepatic
    • ≥ 50 mL/min (based on Cockcroft-Gault estimation Formulas for calculation)
    • (PT), international normalized ratio (INR) or partial thromboplastin time ≤ 1.5 × ULN. Patients on a stable, maintenance regimen of anticoagulant therapy for at least 30 days prior to study drug administration may have PT/INR measurements >1.5 × ULN if, in the opinion of the investigator, the patient is suitable for the study. An adequate rationale must be provided to the sponsor prior to randomization.
  • Resolution of all toxicities from prior therapy to ≤Grade 1 (or baseline) within 1 week prior to the first dose of study drug (excluding alopecia and ≤ Grade 3 clinically asymptomatic lipase, amylase, and creatine phosphokinase laboratory abnormalities).
  • Patient is capable of understanding and complying with the protocol. Subjects should sign the written informed consent before any study-related procedures were performed.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any other in addition to imatinib for advanced GIST. Imatinib-containing combination therapy in the first-line treatment should not be enrolled.
  • Patients with a prior or concurrent whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible.
  • Patient has known active central nervous system .
  • class II - IV heart disease, myocardial infarct, active ischemia or any other uncontrolled cardiac condition within the first 6 months of the first dose of study drug such as angina pectoris, cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
  • (LVEF) \< 50%.
  • Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.
  • Venous thrombotic events (e.g. deep vein thrombosis) or pulmonary arterial events (e.g. pulmonary embolism) within 1 month before the first dose of study drug. Patients on stable anticoagulation therapy for at least one month are eligible.
  • 12-lead (ECG) demonstrating corrected by Fridericia's formula > 450 ms in males or > 470 ms in females at screening or history of long QT interval syndrome.
  • Use of strong or moderate inhibitors and/or inducers of cytochrome P450 (CYP) 3A4 within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of study drug, including certain herbal medications (eg, St. John's Wort) and consumption of grapefruit or grapefruit juice within 14 days prior to the first dose of study drug.
  • Use of known substrates or inhibitors of breast cancer resistance protein (BCRP) transporters within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of study drug.
  • Major surgeries (e.g. abdominal laparotomy) within 4 weeks of the first dose of study drug; all major surgical wounds must be healed and free of infection or dehiscence before the first dose of study drug.
  • Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
  • Known or infection only if the patient is taking medications that are excluded per protocol, virus (HBV) DNA > 2000 IU/ml or > 104 copies/ml.
  • Female patients who are pregnant or lactating or who plan to become pregnant during the study treatment period.
  • Known to any component of the study drug. Patients with Stevenson Johnson syndrome in previous TKI treatment need to be excluded.
  • Gastrointestinal abnormalities including but not limited to:

    • inability to take oral medication
    • malabsorption syndrome
    • Requiring intravenous nutrition
  • Any active hemorrhages, excluding hemorrhoids or gum bleeding.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Ripretinib

    50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle.

    Drug: Ripretinib

  • Active comparator
    Sunitinib

    12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break.

    Drug: Sunitinib

Interventions

  • Oral kinase inhibitor

    Also known as: DCC-2618

  • second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time interval from randomization to the first occurrence of progressive disease based on assessment of the independent radiology review (IRR) or death due to any causes.

    Time frame: Approximately 12 months.

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage of participants whose efficacy is confirmed as complete response (CR) or partial responses (PR) based on independent radiology review.

    Time frame: Approximately 12 months.

  2. Disease Control Rate (DCR)

    The percentage of participants whose efficacy is confirmed as complete response (CR) or partial responses (PR) or duration of SD ≥ 12 months based on independent radiology review.

    Time frame: Approximately 12 months.

07

Results

Posted Jan 15, 2025

Participant flow

108 patients were randomized.

Participant flow — Overall Study
MilestoneRipretinibSunitinib
Started5454
Completed1315
Not completed4139
Withdrew: Remained on treatment1914
Withdrew: Survival follow-up stopped2225

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as the time interval from randomization to the first occurrence of progressive disease based on assessment of the independent radiology review (IRR) or death due to any causes.

Time frame:
Approximately 12 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsRipretinibSunitinib
Progression-free Survival (PFS)10.3 (5.5 to NA)8.3 (4.9 to NA)
SecondaryObjective Response Rate (ORR)

The percentage of participants whose efficacy is confirmed as complete response (CR) or partial responses (PR) based on independent radiology review.

Time frame:
Approximately 12 months.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsRipretinibSunitinib
Objective Response Rate (ORR)1611
SecondaryDisease Control Rate (DCR)

The percentage of participants whose efficacy is confirmed as complete response (CR) or partial responses (PR) or duration of SD ≥ 12 months based on independent radiology review.

Time frame:
Approximately 12 months.
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsRipretinibSunitinib
Disease Control Rate (DCR)2420

Adverse events

Collected over Approximately 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ripretinib13/54 (24.1%)9/54 (16.7%)54/54 (100%)
Sunitinib15/54 (27.8%)12/54 (22.2%)54/54 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventRipretinibSunitinib
Gastrointestinal HaemorrhageGastrointestinal disorders3/541/54
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/542/54
PyrexiaGeneral disorders0/542/54
Upper gastrointestinal haemorrhageGastrointestinal disorders0/542/54
Intestinal obstructionGastrointestinal disorders1/541/54
AnaemiaBlood and lymphatic system disorders1/541/54
CholecystitisHepatobiliary disorders1/540/54
Lower gastrointestinal haemorrhageGastrointestinal disorders1/540/54
HypoaesthesiaNervous system disorders1/540/54
Muscular weaknessMusculoskeletal and connective tissue disorders1/540/54
Most frequent other events
Showing 10 of 73
Most frequent other events
EventRipretinibSunitinib
Neutrophil count decreasedInvestigations1/5442/54
White blood cell count decreasedInvestigations1/5441/54
AnaemiaBlood and lymphatic system disorders17/5440/54
Platelet count decreasedInvestigations3/5434/54
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders13/5429/54
AlopeciasSkin and subcutaneous tissue disorders27/543/54
MyalgiaMusculoskeletal and connective tissue disorders23/544/54
HypertesionVascular disorders16/5420/54
Blood bilirubin increasedInvestigations17/5419/54
HypothyroidismEndocrine disorders10/5417/54

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RipretinibSunitinibTotal
<=18 years000
Between 18 and 65 years353974
>=65 years191534
Age, Continuous
Age, Continuous(years)RipretinibSunitinibTotal
Median59 (25 to 82)58.5 (28 to 81)59 (25 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)RipretinibSunitinibTotal
Female182139
Male363369
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RipretinibSunitinibTotal
American Indian or Alaska Native000
Asian5454108
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)RipretinibSunitinibTotal
China5454108
08

Study locations

18 sites
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality, China
  • The General Hospital of Peking University
    Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Chongqing Medical Universty
    Chongqing, Chognqing, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • The Cancer Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The sixth Affiliated hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • The 4th Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Affiliated Hospital of Haerbin MedicalUniversity
    Harbin, Heilongjiang, China
  • Union Hospital of HUST
    Wuhan, Hubei, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Fudan University Cancer Hospital
    Shanghai, Shanghai Municipality, China
  • Fudan University, Zhongshan Hospital
    Shanghai, Shanghai Municipality, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • The Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2022, 19 months.

Results were first posted in Jan 2025, 2 years 5 months after primary completion.

Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2020
First posted
Nov 18, 2020
StartActual
Nov 25, 2020
Primary completionActual
Jul 20, 2022
CompletionActual
Jul 20, 2022
Results first posted
Jan 15, 2025
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04633122
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Nov 25, 2020
Primary completion
Jul 20, 2022
Completion
Jul 20, 2022
Results posted
Jan 15, 2025
Last update
Apr 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ripretinib

Start the discussion